Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZymeworksZYME -2.48%63 Debt-to-Equity is 0.20 as of Jun. 2026, which is 233% above its 10-year median of 0.06. GuruFocus rates ZYME with a GF Score™ of 63/100 and a GF Value™ of $17.81 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 965 Biotechnology companies, Zymeworks ranks worse than 54.92% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Zymeworks's Debt-to-Equity or its related term are showing as below:
ZYME'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.5 Med: 0.06 Max: 0.5
Current: 0.2
During the past 12 years, the highest Debt-to-Equity Ratio of Zymeworks was 0.50. The lowest was -0.50. And the median was 0.06.
ZYME's Debt-to-Equity is ranked worse than 54.92% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs ZYME: 0.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zymeworks Debt-to-Equity Related Terms
Zymeworks Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Zymeworks's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYME vs MPLT, SRPT, GENB: Debt-to-Equity Comparison
For the Biotechnology subindustry, Zymeworks's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zymeworks Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zymeworks's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zymeworks's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (ZYME) has a Debt-to-Equity of 0.20 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zymeworks and its competitors. This is 233% above median its historical median of 0.06. According to the industry distribution chart, Zymeworks ranks #530 out of 965 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Zymeworks' Debt-to-Equity too high?
Zymeworks' current Debt-to-Equity of 0.20 is 233% above median its 10-year median of 0.06. The Biotechnology industry median Debt-to-Equity is 0.15. Zymeworks' value of 0.20 is 33.3% above this industry median. Based on the distribution chart, Zymeworks ranks #530 out of 965 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zymeworks has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Debt-to-Equity compare to MPLT and SRPT?
According to the Biotechnology industry distribution chart, Zymeworks ranks #530 out of 965 companies for Debt-to-Equity. This places Zymeworks in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Zymeworks' value of 0.20 is 33.3% above this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.15, Zymeworks has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zymeworks's current Debt-to-Equity of 0.20 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zymeworks and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zymeworks's current Debt-to-Equity is 0.20, which is 233% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.81, compared to a current price of $25.12 — trading 41% above its estimated fair value. The current Debt-to-Equity is 0.20, which is 233% above median its 10-year median of 0.06 and 33.3% above the Biotechnology industry median of 0.15. Zymeworks' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zymeworks (ZYME), the current Debt-to-Equity is 0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zymeworks (ZYME) Overvalued in 2026?
Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued.
The current stock price of $25.12 is trading 41% above its estimated GF Value™ of $17.81.
GuruFocus considers Zymeworks to be Significantly Overvalued.
Key valuation signals for ZYME:
Debt-to-Equity: 0.20 (233% above median its 10-year median of 0.06)
GF Value™: $17.81 vs. price of $25.12 (41% above fair value)
Industry Position: 33.3% above the Biotechnology median (#530 of 965)
No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
63GF Score
Get the complete analysis for ZYME
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYME has been successfully added to your 
